



CIN No. : L51909GJ2014PLC078227

GST No. : 24AAECT8906D1ZG

TRIDENT LIFELINE LIMITED

(Formerly Trident Lifeline Private Limited)

Date: 25th October, 2024

BSE Limited 14th Floor, P. J. Towers, Dalal Street, Fort, Mumbai – 400001.	Stock ID: TLL Scrip Code: 543616
--	---

Sub: Earnings Presentation-HY1FY25.

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Earnings Presentation for the half year ended 30th September, 2024 (HY1FY25).

Kindly take the above on record.

Thanking You,

Yours Faithfully

For **Trident Lifeline Limited**

Nikita Sharma
Company Secretary and Compliance Officer
Membership No.: A60595

Encl: As Above

Registered Office: 2004, 2nd Floor, North Extension, Falsawadi, Ring Road, Surat-395003, Gujarat, INDIA.
Tel : +91 261 2451274, 2451284 Email : info@tridentlifeline.com Web : www.tridentlifeline.com

Corporate Office: 2001, 2nd Floor, APMC, Krushi Bazar, Falsawadi, Ring Road, Surat-395003, Gujarat, INDIA.
Tel : +91 261 2490224, 2490225

Lifeline

Q2FY25 Presentation

Trident Lifeline Limited
October 2024



Inside the document

Pg. 03 __ Company Overview

Pg. 09 __ Expansive Product Portfolio

Pg. 14 __ Global Footprint

Pg. 19 __ Leadership

Pg. 21 __ Strategy & Investment Rationale

Pg. 24 __ Financials & Management
Commentary

Contents

A close-up photograph of a metal plate with a grid of small, circular holes. The holes are filled with a bright blue liquid. Above the plate, several vertical metal bars are visible, possibly part of a machine or a filter. The background is blurred, showing more of the machinery.

Company **Overview**

1

Introduction to Trident Lifeline

About us

Trident Lifeline Limited (“Trident Lifeline” or “the Company”) is a fast-growing pharmaceutical Company with business operations spanning formulations under its own brands, loan license model and contract manufacturing model.

Trident has a formidable presence in India, as well as African, Latin America, and East Asian countries.



Vision

To be a leading pharmaceutical company globally by providing high-quality, affordable, and innovative solutions in medicine and treatment.



Mission

To make a distinguished position in pharmaceutical exports through unparalleled quality and reliability.

A growing force in **pharmaceutical formulations export**

945

Export market products registered

2,016

Export market product registrations in process

40

Countries present in globally

Asset-light third-party contract manufacturing model

Third-party

Contract manufacturing model

Strategic M&A

Strategic investments in valuable manufacturing assets to strengthen existing business model

Note – Product Registration Data as on June 30, 2024

Superior Business Model



A growing force in pharmaceutical formulations export

945

Export market products registered

2,016

Export market product registrations in process

40

Countries present in globally

Asset-light third-party contract manufacturing model

Asset-light

Contract manufacturing model, thus entailing limited direct investment in manufacturing capacities

State-of-art

State-of-art units catering to Trident's growing requirements

Strategic M&A

Select strategic investments in valuable manufacturing assets to strengthen business model & supply chain

Superior sales & marketing network

Sales team

Dedicated in-house sales and marketing team


Distribution

Associated with many global dealers & distributors, B2B channel partners and merchant exporters

Regional heads

Dedicated country & continent heads to penetrate deeper in all key markets

Presence across Value Chain



Complete control over supply-chain, procurement done by Trident Lifeline including:

- Raw Materials
- Packaging Materials



- Third-party contract manufacturing
- Contract manufacturing at multiple plants registered with respective foreign healthcare authorities



- Engaged in direct exports under own brands & product registrations
- In addition, also engages in bulk exports to B2B players, or via merchant exporters



- Dedicated sales & marketing team for branded sales
- On ground dealers & distributors
- *Ultimate goal is to **establish brand recall for own brands** in each export market*


Strengthening Presence Across Value Chain

Strategic Acquisition of TNS Pharma Private Limited



51% Total Equity Stake Acquired	April 2024 Commissioned Manufacturing Facility
Classified as a subsidiary with effect from 21 st December 2022	Sachin GIDC Manufacturing Facility Located at:

Commissioned Manufacturing Capacity at TNS



Strengthening Presence Across Value Chain (continued)

Strategic Acquisition of **TLL Herbal Limited**



51%
Total Equity Stake Acquired
on 10th August 2023

In the business of herbal products.

Wholly Owned Subsidiary **TLL Elements Private Limited**



100%
Incorporated Wholly Owned
Subsidiary on 15th April 2024

In the manufacturing, trading, and distribution of skin and hair cosmetic products, including herbal and ancillary items, both in India and internationally.

Holding stake in **Tricorp Industries**



6.21%
Total Equity Stake*

In the business of intermediates for specialty chemicals, agrochemicals, adhesives, human & veterinary APIs.

*Due to allotment of equity shares to other members holding reduced from 18% to 6.21%.



Expansive
**Product
Portfolio**

2

Expansive Product Portfolio

The Company's growing portfolio of products spans over



Product Categories

12



Therapeutic Categories

16



Product categories

- ▶ Anti Bacterial
- ▶ Anti Diarrheal
- ▶ Anti Fungal
- ▶ Anti Malarial
- ▶ Anti Diabetic
- ▶ Dental Cure
- ▶ Proton Pump Inhibitor
- ▶ Anti Protozoal
- ▶ Anti Histamine
- ▶ Anti Hypertensive drugs
- ▶ Anti Lipidemic Drug
- ▶ Anti Parasitic
- ▶ Multivitamin
- ▶ Multimineral
- ▶ Nutraceutical
- ▶ Non-steroidal anti-inflammatory drug (NSAIDS)



Expansive Product Portfolio (continued)

The Company's growing portfolio of products spans over



Product Categories

12



Therapeutic Categories

16





Product categories

- ▶ Capsule
- ▶ Tablet
- ▶ Liquid Ointment
- ▶ Gel
- ▶ Ice Gel
- ▶ Mouthwash
- ▶ Paste
- ▶ Solution
- ▶ Suspension
- ▶ Toothpaste
- ▶ Syrup
- ▶ Cream



Expansive Product Portfolio (continued)

2,960+
Products in Portfolio



Expansive Product Portfolio (continued)



Tablets are by far the largest product category accounting for 48% of the revenue



Followed by **suspensions** being the second largest category which accounts for 15% of the revenue.



Other categories include toothpaste, mouthwash and other ointments accounting 14% of the revenue.




The product mix has remained fairly-stable over the years with tablets contributing the highest revenue.



Going forward, the Company plans on **adding more formulation categories** in its portfolio.

Revenue Break-up: Product Categories

(In %)





Growing **Global Footprint**

3

Growing Geographical Footprint

Trident Lifeline has a **growing geographical footprint** and a formidable presence export markets such as African, Latin American, CIS and East Asian countries.




23

Countries where products are registered



40

Countries where products are under registration



Map not to scale

Geographical Revenue Mix

Being an **export-oriented Company**, Trident has been constantly growing its export business

The share of exports have increased from 55% in FY20 to 59% in FY24


- **Africa** is a major export market for the company
- Followed by increasing share in **South American market**

Other key markets for the Company include

- India
- Venezuela
- Cameroon


Revenue Break-up: Exports & Domestic

(In %)



Revenue Break-up: Continent-wise

(In %)



Note – Exports also includes merchant exports

Bolstering Export Growth



Trident Lifeline has been making consistent, upfront investments in **export product registrations** to bolster revenue growth



Export product registrations are a painstaking task, involving **significant gestation period** of 1.5 to 3 years.



The Company also needs to register the facilities of its contract manufacturing partners before beginning product registrations.



Till date, the Company has **2,961 product registration applications**, of which 945 have been registered, and many of the pending applications are in advance stages of registrations

Note – Product Registration Data as on September 30, 2024




Bolstering Export Growth (continued)

Ghana, Venezuela, Cambodia & Kenya combined accounts for ~60% the total product registered and under registration.

TLL has 650+ products registrations filed in **Venezuela**, followed by Ghana, Cambodia and Kenya.

Increasing efforts in markets like South America and Africa.

Country-wise product bifurcation
(In %)



Venezuela	654	Nigeria	89
Ghana	598	Cameroon	61
Cambodia	260	Myanmar	70
Kenya	275	Georgia	57
Peru	204	Phillipines	94
Bolivia	152	Others	447

Note – Data as on September 30, 2024



Leadership

4

Board of Directors

Mr. Hardik Jigishkumar Desai

Mr. Hardik Jigishkumar aged 45 years is Promoter-Chairman and Executive Director of the Company.

He possess 9 years of experience in the field of pharmaceuticals and decades of experience in textiles. He is responsible for the overall management of the Company.

Mr. Shravan Harikrishna Patel

Mr. Shravan Harikrishna Patel aged 29 years is Managing Director of the Company.

He possess 4 years of experience in the field of pharmaceuticals. He is responsible for the procurement function of the Company.

Mrs. Rupaben Chetan Jariwala

Mrs. Rupaben Chetan Jariwala is Whole Time Director of the Company.

She possesses 5 years of experience in the field of pharmaceuticals. She holds a Bachelor of Commerce degree and has been actively engaged in our company's operations since April 2017.

Mrs. Maniya Hardik Desai

Mrs. Maniya Hardik Desai aged 38 Years is Non- Executive Director of the Company.

She possess 6 years of experience in the field of pharmaceuticals.

Dr. Mishal Shailesh Patel

Dr. Mishal Shailesh Patel is an Independent Director of the Company.

Dr. Patel is a consultant pediatric surgeon at numerous hospitals. His qualifications includes MBBS, MS (General Surgery), MCh (Pediatric Surgery) Gold Medalist, MRCS (Edinburgh).

Mrs. Falguni Bhavesh Jariwala

Mrs. Falguni Bhavesh Jariwala has been recently inducted as an Independent Director to the Company.

Mrs. Patel is an Admin Manager and CAS Coordinator at Fountainhead School, Surat. She holds a degree in Bachelor of Home Science from SNDT University, Mumbai.



Strategy & Investment Rationale

5

Strategic Priorities



Continuous investments in product registrations

- **300-400** additional product registrations each year
- **₹5-6 crore** of capital outlay for product registrations each year



Expanding intellectual property registrations

- Registering brand's trademark – **65** brands registered so far
- **Strengthen brand recall** and build B2C business in export markets



Strengthening supply chain

- Strengthening strategic tie-ups with third-party contract manufacturers
- Getting contract manufacturers WHO-GMP certified, and accredited from other global healthcare authorities



Building sales & marketing prowess

- Expanding dedicated **sales & marketing team**
- Appoint **country & geographical sales heads** for each key market



Expand product portfolio

- Grow product portfolio in a clustered manner, with **at least 50-100 registrations** in each key market
- Add newer formulations & therapeutic categories in the portfolio
- Adding molecules going off-patent in coming years

Investment Rationale

- Trident's business model reaps **backloaded investment benefits** of product registrations
- Current product registration investments will reap benefits after 2-3 years

Exponential growth model

Extensive product registrations awaited

- 2,016 registrations in pipeline spread over 40 countries, with many **registrations under advance stages of the approval**
- Post registrations, potential to grow top line significantly

- Investments in manufacturing capacities are made by third-party contract manufacturers
- Trident's investments are limited to product registrations and sales & marketing efforts, allowing for **superior ROCEs as the business scales-up**

Asset-light model

Growing focus on recently off-patent molecules

- The Company is increasing focus on **molecules going off-patent** in developed markets
- Introduction of these molecules in Company's market possesses superior growth opportunities & potential for better profitability margins



Financials & Management **Commentary**

6

Quarterly Profit & Loss Snapshot

(₹ in Lakh)

Particulars	Q2FY25	Q1FY25	Q2FY24	YOY Change (%)
Total Revenue	1,598.73	1,430.45	498.20	221%
Total Operating Expenses	1,139.83	1,065.62	455.22	150%
EBITDA	458.90	364.83	42.98	968%
EBITDA (%)	29%	26%	9%	2,007 BPS
Interest Cost	49.76	49.37	8.52	484%
Depreciation & Amortisation	15.70	54.37	5.99	162%
Profit Before Taxes	393.44	261.09	28.47	1,282%
Profit After Taxes	280.97	160.09	61.95	354%
Earnings Per Share (₹)	2.69	1.99	0.54	398%

Note – Consolidated Financials

+221% YOY
Revenue growth in Q2FY25

+968% YOY
EBITDA growth in Q2FY25

+354% YOY
PAT growth in Q2FY25

Management Commentary

- Trident Lifeline continues with its robust performance, following a robust start to the financial year. Revenue for Q2FY25 stood at ₹1,598.73 lakh, registering a substantial 221% YOY increase.
- Profitability margins improved further, with higher operating margins contributing to better PAT growth.
- EBITDA for the quarter was ₹458.90 lakh, a 968% YOY increase, with EBITDA margins at 29% in Q2FY25 as compared to 26% in Q1FY25. Depreciation & amortization costs have also moderated for the quarter, thus aiding PAT growth.
- The outlook for the rest of the financial year remains robust, with business operations expected to expand at both standalone and consolidated levels through Trident Lifeline's strategic organic and inorganic growth strategy.

Note – Consolidated Financials



Annual Profit & Loss Snapshot

(₹ in Lakh)

Particulars	FY20	FY21	FY22	FY23	FY24
Total Revenue	505.63	978.12	2,237.14	3285.02	4670.72
Total Operating Expenses	517.2	836.93	1,905.94	2544.14	3643.79
EBITDA	-11.57	141.2	331.2	740.88	1026.93
EBITDA (%)	-2%	14%	15%	23%	22%
Interest Cost	76.21	41.23	12.58	46.59	60.44
Depreciation & Amortisation	11.54	14.38	20.26	36.47	96.96
Profit Before Taxes	-99.32	85.59	298.36	657.82	869.53
Profit After Taxes	-99.59	93.11	394.77	601.42	593.97
Earning Per Share (₹)	-3.21	2.26	6.92	6.22	5.17

Balance Sheet Snapshot

(₹ in Lakh)

Particulars	FY20	FY21	FY22	FY23	FY24
Shareholders Fund	-500.31	-217.21	477.57	4710.81	5296.00
Application Money Pending Allotment	-	-	-	-	99.00
Non Current Liability	646.93	457.65	148.94	392.83	1287.00
Current Liabilities	286.65	735.61	756.98	1153.40	2025.62
Other Current Liabilities	103.24	333.81	234.10	672.32	1272.05
Trade Payable	183.41	401.8	522.88	481.08	753.57
Total	433.27	976.05	1383.49	6257.04	8707.62
Non Current Assets	161.42	143.57	316.92	1336.07	3510.15
Current Assets	271.85	832.49	1066.57	4920.97	5197.47
Other Current Assets	56.86	254.13	198.76	2995.19	2594.79
Inventories	93.64	527.14	371.2	716.83	1258.40
Trade Receivable	121.35	51.22	496.61	1208.95	1344.28
Total	433.27	976.05	1,382.49	6257.04	8707.62

Cash Flow Snapshot

(₹ in Lakh)

Particulars	FY20	FY21	FY22	FY23	FY24
Cash from Operating Activities	-81.86	-32.02	-21.47	-1900.43	222.51
Cash from Investing Activities	-13.63	24.79	-44.52	-968.71	-2036.38
Cash from Financing Activities	103.75	1.43	80.19	4228.28	1100.82
Net Cash Flow	8.26	-5.8	14.20	1359.14	-713.05
Net Cash at Beginning of Year	4.12	12.38	1.46	18.37	1378.48
Net Cash at the End of Year	12.38	6.58	15.66	1377.51	665.43

Safe Harbour

Get in touch__

Mr. Shravan H. Patel
Managing Director

Trident Lifeline Limited
compliance@tridentlifeline.com

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management of Trident Lifeline Limited ("Company" or "Trident" or "Trident Lifeline"), which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments. This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. This presentation may not be copied or disseminated, in whole or in part, and in any manner.